Childhood Acute Lymphoblastic Leukemia Treatment (PDQ®)–Health Professional Version

SECTIONS

Changes to this Summary (10/12/2016)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Postinduction Treatment for Childhood Acute Lymphoblastic Leukemia (ALL)

Added text to state that in the COG-AALL1131 trial, patients identified as having BCR-ABL1–like ALL and who have a gene fusion involving a kinase that is sensitive to dasatinib are assigned to treatment with dasatinib added to standard chemotherapy. Dasatinib treatment is initiated after induction therapy is complete, and it continues through maintenance therapy.

This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Treatment of Relapsed Childhood ALL

Next section >
About This PDQ Summary